Alexza Pharmaceuticals, Inc.

With its first approved product, BioXcel Therapeutics, Inc. believes it has a differentiated treatment for agitation in schizophrenia and bipolar disorder patients, but the US Food and Drug Administ

UCB Group has hit the acquisition trial to snap up Engage Therapeutics of the US for an upfront payment of $125m, boosting its already strong presence in the epilepsy space. The deal centers around

The US FDA is looking to purchase a generic EpiPen and competing epinephrine products for testing in its labs, potentially to try to determine how competition for it and other combination products cou

The US FDA is looking to purchase a generic EpiPen and competing epinephrine products for testing in its labs, potentially to try to determine how competition for it and other combination products cou